{"keywords": [{"value": "Express Scripts Inc", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "is_major": "Y", "name": "subject"}, {"value": "Repatha (Drug)", "rank": "3", "is_major": "N", "name": "subject"}, {"value": "Praluent (Drug)", "rank": "4", "is_major": "N", "name": "subject"}, {"value": "Cholesterol", "rank": "5", "is_major": "Y", "name": "subject"}, {"value": "AbbVie Inc", "rank": "6", "is_major": "N", "name": "organizations"}, {"value": "Sanofi SA", "rank": "7", "is_major": "N", "name": "organizations"}, {"value": "Gilead Sciences Inc", "rank": "8", "is_major": "N", "name": "organizations"}, {"value": "Amgen Inc", "rank": "9", "is_major": "N", "name": "organizations"}, {"value": "Regeneron Pharmaceuticals Inc", "rank": "10", "is_major": "N", "name": "organizations"}], "headline": {"print_headline": "Express Scripts Will Cover 2 New Cholesterol Drugs", "main": "Express Scripts Says It Will Cover 2 New Cholesterol Drugs"}, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "POLLACK", "firstname": "Andrew"}]}, "web_url": "http://www.nytimes.com/2015/10/07/business/express-scripts-says-it-will-cover-2-new-cholesterol-drugs.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "News", "_id": "5614368738f0d81ce51124e1", "multimedia": [], "pub_date": "2015-10-07T00:00:00Z", "print_page": "4", "section_name": "Business Day", "word_count": "772", "blog": [], "news_desk": "Business", "snippet": "Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products.", "document_type": "article", "abstract": "Express Scripts says it will pay for drugs Repatha and Praluent, two of promising new kind of cholesterol-lowering medicines that can be prohibitively expensive for most Americans; Express Scripts is largest manager of drug prescriptions, and industry experts had wondered if it would only pick one of two competing drugs to cover.", "lead_paragraph": "Rather than bargain with a single maker, the pharmacy benefits manager says it will offer both Repatha and Praluent, promising but expensive products."}